Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT01697566
Other study ID # 2011-0739
Secondary ID 5P50CA098258NCI-
Status Active, not recruiting
Phase Phase 3
First received
Last updated
Start date May 2, 2013
Est. completion date May 30, 2025

Study information

Verified date May 2024
Source M.D. Anderson Cancer Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of this clinical research study is to learn about the effects of metformin and/or a program called "lifestyle intervention" on the endometrium (inner lining of the uterus) in post-menopausal women who are also obese (both are risk factors for endometrial cancer). Researchers also want to learn how insulin levels will be affected by metformin, diet and/or exercise. Metformin is designed to treat both diabetes and insulin resistance. Insulin resistance is a condition in which the body makes insulin but does not use it properly. It is often referred to as "pre-diabetes". Many people with insulin resistance have high levels of both sugar and insulin in their blood at the same time, which have been reported in patients with endometrial cancer. In this study, metformin will be compared to a placebo. A placebo is not a drug. It looks like the study drug but is not designed to treat any disease or illness. It is designed to be compared with a study drug to learn if the study drug has any real effect. Lifestyle intervention is made up of a series of in-person sessions where you meet with a coach to discuss strategies for losing weight and ways to increase physical activity. It also consists of materials designed to help you lose weight and will offer opportunities for supervised exercise.


Description:

Study Groups: If you are found to be eligible to take part in this study, you will be randomly assigned (as in the roll of dice) to 1 of 4 study groups: - Metformin only. - Placebo and lifestyle intervention. - Metformin and lifestyle intervention. - Placebo only. Neither you nor the study staff will know if you are receiving metformin or placebo. However, if needed for your safety, the study staff will be able to find out what you are receiving. In the first month you will gradually increase the dose of metformin/placebo by mouth as listed below: - Week 1: One capsule each day - Week 2: One capsule 2 times each day - Week 3: One capsule 3 times each day - Week 4: Two capsules 2 times each day After week 4, you will continue to take 2 capsules of metformin/placebo 2 times each day. If you are receiving the lifestyle intervention, you will have 16 lifestyle intervention sessions over 4 months. At each of these sessions, you will discuss methods for managing your weight. You will receive print materials and worksheets, measuring utensils, and a food scale. You will be instructed how to use each of these materials and how often to use them during the study. You will also be provided with opportunities for supervised exercise (such as group exercise class and group walks). If you are traveling during a scheduled session, it can be performed over the telephone. Each call should last about 30 minutes, during which you will discuss the same goals and information that you would discuss in the in-person sessions. Study Visits: Before you can begin receiving the study drug/placebo: - At the second screening visit , you will have a dual energy x-ray absorptiometry (DEXA) scan to measure your body composition. The scan requires you to lie still on a table for about 8-10 minutes while a low-energy x-ray takes an image that allows the study staff to get an image of your body fat density. - You will be given an accelerometer (a small, portable device that measures your physical activity) and be taught how to use it at the first Screening Visit. You will wear the accelerometer at all times while you are awake for 7 days. At the second Screening Visit, you will return the accelerometer at an intervention session. If you are not able to return it at the second visit then you will mail it back to the study staff in a pre-paid envelope. You will receive the accelerometer again at Month 4 and wear it for another 7 days. - You will receive a study diary in which you will record any and all exercise you perform each day while you are on study. It should take about 5 minutes to complete each time. - You will complete questionnaires about diet and exercise. These questionnaires should take about 30-40 minutes to complete. - You will also be taught to complete a questionnaire on the internet to record the food you eat in a 24 hour period. You will do this 3 times over a 2 week period. The first time, you will complete it at the clinic. The study staff will call and remind you to complete the questionnaire the other 2 times. Each time you complete this questionnaire, it should take about 40 minutes. At Month 1, all participants will return for a study visit. The following tests and procedures will be performed: - Blood (about 2 teaspoons) will be drawn for routine tests. If this blood draw shows that your liver or kidney function is abnormal, you will need to return for an additional blood °draw at Month 2. - If you are having symptoms that you would describe as moderate or worse, you will have a non-pelvic physical exam including measurement of your vital signs and any unreported symptoms you may be having. At each month, you will be asked about any symptom(s) that you may have to learn if it is related to the study. If you are called, this phone call should last about 5 minutes. If you are asked in a in-person visit, the visit can last up to an hour. Length of Study: You will receive the study drug/placebo and/or lifestyle intervention for up to 4 months. You will be taken off study if you have intolerable side effects or if you develop endometrial cancer or hyperplasia during the study. Your participation in the study will be over after the end-of-study visit. Post-Treatment Visit: At the end of the 4th month, you will have a post-treatment visit. You will repeat all procedures performed in the first and second visit: - Your height, weight, waist, and hip circumference will be measured. - You will have a DEXA scan. - You will complete the questionnaires about food, diet, and exercise. - You will be given a questionnaire about your satisfaction (based on the intervention) to complete and return at this visit. This questionnaire will take up to an hour to complete. - You will have an endometrial biopsy. - Blood (about 8 tablespoons) will be drawn for routine tests and for biomarker testing. You will have to fast (not eat or drink anything except water) for 12 hours before this blood draw. - You will complete the questionnaire on the internet to record the food you eat in a 24 hour period. You will do this 3 times over a 2 week period. The first time, you will complete it at the clinic. The study staff will call and remind you to complete the questionnaire the other 2 times. Each time you complete this questionnaire, it should take about 40 minutes. Follow-Up: About 1 year after the screening visits (+/- 1 month), the following tests and procedures will be performed: - Your height, weight, waist, and hip circumference will be measured. - You will have a DEXA scan. - Blood (about 8 tablespoons) will be drawn for routine tests and for biomarker testing. °You will have to fast (not eat or drink anything except water) for 12 hours before this blood draw. - You will wear the accelerometer for 7 days. - You will complete questionnaires about food, diet, and exercise. - You will complete the questionnaire on the internet to record the food you eat in a 24 hour period. You will do this 3 times over a 2 week period. The first time, you will complete it at the clinic. The study staff will call and remind you to complete the questionnaire the other 2 times. Each time you complete this questionnaire, it should take about 40 minutes. This is an investigational study. Metformin is FDA approved and commercially available for the treatment of diabetes and insulin resistance. Up to 100 patients will take part in this study. All will be enrolled at MD Anderson Cancer Center.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 100
Est. completion date May 30, 2025
Est. primary completion date May 30, 2025
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 50 Years to 65 Years
Eligibility Inclusion Criteria: 1. For this study, only women will be enrolled. 2. Body Mass Index (BMI) > or = 30 kg/m2 3. Not frankly diabetic, as measured by a fasting blood glucose </=126 mg/dL. 4. Demonstrate hyperinsulinemia with a QUICK I value </= 0.357. 5. Age >/= 50 and </= 65 6. Zubrod Performance Scale 0-1 7. Hemoglobin >/= 10 g/dl 8. TSH 0.27 - 4.20 µlU/mL 9. Menopause as defined as no menses for 1 year and/or FSH >/= 25.8 mIU/ml 10. Must be able to read, write, and speak English. 11. Must have a Primary Care Provider (PCP). Exclusion Criteria: 1. Prior hysterectomy or endometrial ablation 2. ALT >/r = 2.0x Upper Limit of Normal (ULN) 3. Serum creatinine > /= 1.4 mg/dl 4. Triglycerides (fasting) >/ = 400 5. Known inability to participate in the ongoing appointments for the four months of the study and scheduled follow-up tests. 6. Significant medical or psychiatric history which would make the participant a poor protocol candidate, in the opinion of the principal investigator, for any aspect of study participation including metformin, unsupervised exercise program or dietary behavior change. 7. Participant reported history of congestive heart failure 8. Prior treatment with Metformin 9. Currently being treated for diabetes or meeting criteria for new diagnosis of diabetes. 10. Known allergy to Metformin or other biguanide (Proguanil). 11. Use of Aromatase Inhibitors, GNRH-agonists i.e.Lupron, Zoladex within the last 6 months 12. Use of SERMS (selective estrogen receptor modulators) in the past 6 months, including Tamoxifen and Raloxifene 13. Hormone replacement therapy within the last 6 months 14. Women who have been treated with chemotherapy for prior malignant disease or currently have an untreated malignancy other than non-melanoma skin cancer 15. Patients who have had prior radiation to the pelvis

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Metformin
Participants gradually increase the dose of metformin by mouth as listed below: Week 1: One capsule each day Week 2: One capsule 2 times each day Week 3: One capsule 3 times each day Week 4: Two capsules 2 times each day After week 4, participant continues to take 2 capsules of metformin 2 times each day. Each capsule is 425 mg.
Other:
Placebo
Placebo taken by mouth twice daily for 4, 30 day cycles.
Procedure:
Endometrial Biopsy
Endometrial biopsies obtained at baseline and after 4 months.
Behavioral:
Lifestyle Intervention
Lifestyle intervention consists of 16 in-person sessions offered over a 4 month period.
Questionnaires
Completion of questionnaires about diet and exercise at baseline, during treatment and at end of study. Questionnaires take about 30-40 minutes to complete.

Locations

Country Name City State
United States University of Texas MD Anderson Cancer Center Houston Texas

Sponsors (2)

Lead Sponsor Collaborator
M.D. Anderson Cancer Center National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Effect of Metformin and/or Lifestyle Intervention on Biomarkers. Differences in Ki-67 and other biomarkers analyzed using a 2x2 ANOVA. Other biomarkers examined include a) a panel of genes relevant to estrogen dependent endometrial proliferation, hyperplasia and cancer using Q-PCR, b) biomarkers specific to the effect of metformin treatment (phospho-AMPKa, phospho-ACC, phospho-mTOR and phospho-S6 ribosomal protein and c) potential biomarkers of modulation of insulin sensitivity on the human endometrial proteome using reverse phase protein arrays (RPPA). 4 months
See also
  Status Clinical Trial Phase
Completed NCT04059328 - Novel Surgical Checklists for Gynecologic Laparoscopy in Haiti
Completed NCT02638688 - Measurement of Fibroid Volume and 2D, 3D US N/A
Not yet recruiting NCT02769325 - Atropine in Laparoscopic Gynaecological Surgery Phase 4
Recruiting NCT06388590 - Acupuncture for Chronic Pelvic Pain N/A
Withdrawn NCT04089852 - Nitrous Oxide for Pain Management During IUD Insertion in Nulliparous Adolescent Women Phase 2/Phase 3
Recruiting NCT03589352 - Women's Knowledges About Gynaecological Aftercare
Recruiting NCT04737473 - The Comparative Efficacy and Safety of Two General Anesthesia Protocols Consisting of Fentanyl Plus Propofol Plus Rococuronium Plus Isoflurane Versus Ketamime Plus Magnesium Sulphate Plus Lidocaine Plus Clonidine Plus Propofol Plus Rococuronium Plus Isoflurane for Gynaecology Surgery in Cameroon N/A
Recruiting NCT05757011 - the Effect of Pre-sacral Nerve Block on Post-operative Pain Following Laparoscopic Hysterectomy N/A
Completed NCT02274441 - Activity and Quality of Care Indicators' for a Sentinel Network Creation N/A
Completed NCT03805386 - Patient-Directed Postoperative Opioid Prescribing for Gynecologic Surgery Phase 2/Phase 3
Completed NCT06324019 - Gynaecological Examination Gown and Patient Satisfaction N/A
Recruiting NCT06394752 - UTERINE EVALUATION FOR THE IDENTIFICATION OF PATHOLOGY. This Study Will Compare the Intrauterine Pathology Detection Rate Between Standard of Care Hydrosonography, and a New Visual Saline Infusion Device Providing Direct Visualization of the Uterus. N/A
Completed NCT02800031 - IOTA Versus Pattern Recognition Method in Diagnosis of Ovarian Masses N/A